Primary Graft Dysfunction

Clinics in Chest Medicine

Volumn 32, Issue 2, 2011, Pages 279-293

  Lee, James C ^a   Christie, Jason D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarkers; Bronchiolitis obliterans syndrome; Lung transplantation; Primary graft dysfunction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; COLLAGEN TYPE 5; NITRIC OXIDE;

AGE; BRONCHIOLITIS OBLITERANS; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; GRAFT RECIPIENT; HUMAN; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN DONOR; OUTCOME ASSESSMENT; PATHOGENESIS; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURGICAL RISK;

BIOLOGICAL MARKERS; HUMANS; LUNG TRANSPLANTATION; PRIMARY GRAFT DYSFUNCTION; RISK FACTORS;

EID: 79954598739     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.02.007     Document Type: Review

References (94)

1. Christie J.D., Bavaria J.E., Palevsky H.I., et al. Primary graft failure following lung transplantation. Chest 1998, 114(1):51-60.
2. King R.C., Binns O.A., Rodriguez F., et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000, 69(6):1681-1685.
3. Christie J.D., Kotloff R.M., Pochettino A., et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003, 124(4):1232-1241.
4. Arcasoy S.M., Kotloff R.M. Lung transplantation. N Engl J Med 1999, 340(14):1081-1091.
5. Christie J.D., Van Raemdonck D., de Perrot M., et al. Report of the ISHLT working group on primary lung graft dysfunction part I: introduction and methods. J Heart Lung Transplant 2005, 24(10):1451-1453.
6. Arcasoy S.M., Fisher A., Hachem R.R., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant 2005, 24(10):1483-1488.
7. Christie J.D., Carby M., Bag R., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005, 24(10):1454-1459.
8. Daud S.A., Yusen R.D., Meyers B.F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007, 175(5):507-513.
9. Lee J.C., Christie J.D. Primary graft dysfunction. Proc Am Thorac Soc 2009, 6(1):39-46.
10. Lee J.C., Christie J.D., Keshavjee S. Primary graft dysfunction: definition, risk factors, short- and long-term outcomes. Semin Respir Crit Care Med 2010, 31(2):161-171.
11. Christie J.D., Sager J.S., Kimmel S.E., et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005, 127(1):161-165.
12. Fiser S.M., Kron I.L., McLendon Long S., et al. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 2001, 20(6):631-636.
13. Khan S.U., Salloum J., O'Donovan P.B., et al. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response. Chest 1999, 116(1):187-194.
14. Prekker M.E., Nath D.S., Walker A.R., et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006, 25(4):371-378.
15. Christie J.D., Bellamy S., Ware L.B., et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010, 29:1231-1239.
16. Huang H.J., Yusen R.D., Meyers B.F., et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant 2008, 8(11):2454-2462.
17. 2/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest 2007, 132(3):991-997.
18. Oto T., Levvey B.J., Snell G.I. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant 2007, 26(5):431-436.
19. Christie J., Keshavjee S., Orens J., et al. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant 2008, 27(1):138.
20. Whitson B.A., Prekker M.E., Herrington C.S., et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007, 26(10):1004-1011.
21. Fiser S.M., Tribble C.G., Long S.M., et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002, 73(4):1041-1047. [discussion: 1047-8].
22. Fisher A.J., Wardle J., Dark J.H., et al. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002, 21(11):1206-1212.
23. Girgis R.E., Tu I., Berry G.J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996, 15(12):1200-1208.
24. Hachem R.R., Khalifah A.P., Chakinala M.M., et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005, 80(10):1406-1413.
25. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005, 5(8):2022-2030.
26. de Perrot M., Liu M., Waddell T.K., et al. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003, 167(4):490-511.
27. Frank M.M. Complement in the pathophysiology of human disease. N Engl J Med 1987, 316(24):1525-1530.
28. Covarrubias M., Ware L.B., Kawut S.M., et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007, 7(11):2573-2578.
29. Moreno I., Vicente R., Ramos F., et al. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc 2007, 39(7):2425-2426.
30. Miotla J.M., Jeffery P.K., Hellewell P.G. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am J Respir Cell Mol Biol 1998, 18(2):197-204.
31. Serrick C., Adoumie R., Giaid A., et al. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994, 58(11):1158-1162.
32. Barr M.L., Kawut S.M., Whelan T.P., et al. Report of the ISHLT working group on primary lung graft dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 2005, 24(10):1468-1482.
33. de Perrot M., Bonser R.S., Dark J., et al. Report of the ISHLT working group on primary lung graft dysfunction part III: Donor-related risk factors and markers. J Heart Lung Transplant 2005, 24(10):1460-1467.
34. Meyer D.M., Bennett L.E., Novick R.J., et al. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation. Chest 2000, 118(5):1255-1262.
35. Whitson B.A., Nath D.S., Johnson A.C., et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006, 131(1):73-80.
36. Oto T., Griffiths A.P., Levvey B., et al. A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation 2004, 78(4):599-606.
37. Thabut G., Vinatier I., Stern J.B., et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002, 121(6):1876-1882.
38. Christie J.D., Shah C.V., Kawut S.M., et al. Plasma levels of receptor for advanced glycation end-products (SRAGE), blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009, 180(10):1010-1015.
39. Kawut S.M., Okun J., Shimbo D., et al. Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 2009, 136(1):237-244.
40. Lee J.C., Kuntz C., Kawut S.M., et al. Clinical risk factors for the development of primary graft dysfunction. J Heart Lung Transplant 2008, 27(2 Suppl 1):S67-S68.
41. Cassivi S.D., Meyers B.F., Battafarano R.J., et al. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002, 74(5):1663-1669. [discussion: 1669-70].
42. Lee J.C., Hadjiliadis D., Aahya V.N., et al. Risk factors for early vs late primary graft dysfunction. Am J Respir Crit Care Med 2008, 177:A396. [abstract].
43. Fang A., Studer S., Kawut S.M., et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2010, [Epub ahead of print].
44. Sommers K.E., Griffith B.P., Hardesty R.L., et al. Early lung allograft function in twin recipients from the same donor: risk factor analysis. Ann Thorac Surg 1996, 62(3):784-790.
45. Szeto W.Y., Kreisel D., Karakousis G.C., et al. Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome. J Thorac Cardiovasc Surg 2002, 124(2):241-249.
46. Webert K.E., Blajchman M.A. Transfusion-related acute lung injury. Transfus Med Rev 2003, 17(4):252-262.
47. Silliman C.C., Fung Y.L., Ball J.B., et al. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev 2009, 23(6):245-255.
48. Silliman C.C., Boshkov L.K., Mehdizadehkashi Z., et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003, 101(2):454-462.
49. Mangalmurti N.S., Xiong Z., Hulver M., et al. Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation. Blood 2009, 113(5):1158-1166.
50. Wang Y., Kurichi J.E., Blumenthal N.P., et al. Multiple variables affecting blood usage in lung transplantation. J Heart Lung Transplant 2006, 25(5):533-538.
51. Goodwin J., Tinckam K., denHollander N., et al. Transfusion-related acute lung injury (TRALI) in graft by blood donor antibodies against host leukocytes. J Heart Lung Transplant 2010, 29(9):1067-1070.
52. dos Santos C.C., Okutani D., Hu P., et al. Differential gene profiling in acute lung injury identifies injury-specific gene expression. Crit Care Med 2008, 36(3):855-865.
53. Li J., Nie J., Chen G., et al. Gene expression profile of pulmonary tissues in different phases of lung ischemia-reperfusion injury in rats. J Huazhong Univ Sci Technolog Med Sci 2007, 27(5):564-570.
54. Ray M., Dharmarajan S., Freudenberg J., et al. Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation. Am J Transplant 2007, 7(10):2396-2405.
55. Anraku M., Cameron M.J., Waddell T.K., et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant 2008, 8(10):2140-2148.
56. Hadjiliadis D., Chaparro C., Reinsmoen N.L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005, 24(7 Suppl):S249-S254.
57. Yoshida S., Haque A., Mizobuchi T., et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006, 6(4):724-735.
58. Bobadilla J.L., Love R.B., Jankowska-Gan E., et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008, 177(6):660-668.
59. Halloran P.F., Homik J., Goes N., et al. The " injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997, 29(1-2):79-81.
60. Burlingham W.J., Love R.B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007, 117(11):3498-3506.
61. Bharat A., Kuo E., Steward N., et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008, 86(1):189-195. [discussion: 196-7].
62. Bharat A., Saini D., Steward N., et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010, 90(4):1094-1101.
63. Hoffman S.A., Wang L., Shah C.V., et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant 2009, 9(2):389-396.
64. Justice A.C., Covinsky K.E., Berlin J.A. Assessing the generalizability of prognostic information. Ann Intern Med 1999, 130(6):515-524.
65. Calfee C.S., Budev M.M., Matthay M.A., et al. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007, 26(7):675-680.
66. Lysenko L., Mierzchala M., Gamian A., et al. The effect of packed red blood cell storage on arachidonic acid and advanced glycation end-product formation. Arch Immunol Ther Exp (Warsz) 2006, 54(5):357-362.
67. Wautier J.L., Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004, 95(3):233-238.
68. Wilkes D.S. Primary graft dysfunction: it's all the rage. Am J Respir Crit Care Med 2009, 180(10):915-916.
69. Pelaez A., Force S.D., Gal A.A., et al. Receptor for advanced glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation. Am J Transplant 2010, 10(4):900-907.
70. Salama M., Andrukhova O., Hoda M.A., et al. Concomitant endothelin-1 overexpression in lung transplant donors and recipients predicts primary graft dysfunction. Am J Transplant 2010, 10(3):628-636.
71. Shargall Y., Guenther G., Ahya V.N., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 2005, 24(10):1489-1500.
72. Meade M.O., Granton J.T., Matte-Martyn A., et al. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003, 167(11):1483-1489.
73. Botha P., Jeyakanthan M., Rao J.N., et al. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007, 26(11):1199-1205.
74. Moreno I., Vicente R., Mir A., et al. Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation. Transplant Proc 2009, 41(6):2210-2212.
75. Inci I., Erne B., Arni S., et al. Prevention of primary graft dysfunction in lung transplantation by N-acetylcysteine after prolonged cold ischemia. J Heart Lung Transplant 2010, 29:1293-1301.
76. Hirayama S., Cypel M., Sato M., et al. Activated protein C in ischemia-reperfusion injury after experimental lung transplantation. J Heart Lung Transplant 2009, 28(11):1180-1184.
77. Currey J., Pilcher D.V., Davies A., et al. Implementation of a management guideline aimed at minimizing the severity of primary graft dysfunction after lung transplant. J Thorac Cardiovasc Surg 2010, 139(1):154-161.
78. Adatia I., Lillehei C., Arnold J.H., et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994, 57(5):1311-1318.
79. Date H., Triantafillou A.N., Trulock E.P., et al. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996, 111(5):913-919.
80. Macdonald P., Mundy J., Rogers P., et al. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide. J Thorac Cardiovasc Surg 1995, 110(3):861-863.
81. Garat C., Jayr C., Eddahibi S., et al. Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury. Am J Respir Crit Care Med 1997, 155(6):1957-1964.
82. Meyers B.F., Sundt T.M., Henry S., et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000, 120(1):20-26.
83. Smedira N.G., Moazami N., Golding C.M., et al. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years. J Thorac Cardiovasc Surg 2001, 122(1):92-102.
84. Bermudez C.A., Adusumilli P.S., McCurry K.R., et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival. Ann Thorac Surg 2009, 87(3):854-860.
85. Kuntz C.L., Hadjiliadis D., Ahya V.N., et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 2009, 23(6):819-830.
86. Fisher A.J., Donnelly S.C., Hirani N., et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001, 163(1):259-265.
87. De Perrot M., Sekine Y., Fischer S., et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002, 165(2):211-215.
88. Kaneda H., Waddell T.K., de Perrot M., et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006, 6(3):544-551.
89. Krenn K., Klepetko W., Taghavi S., et al. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant 2007, 7(3):700-706.
90. Christie J.D., Robinson N., Ware L.B., et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007, 175(1):69-74.
91. Herrington C.S., Prekker M.E., Arrington A.K., et al. A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. Clin Transplant 2011, 25(1):90-96.
92. Marasco S.F., Pilcher D., Oto T., et al. Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction. Eur J Cardiothorac Surg 2010, 37(2):420-425.
93. Zamora M.R., Davis R.D., Keshavjee S.H., et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999, 116(1 Suppl):46S.
94. Wittwer T., Grote M., Oppelt P., et al. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001, 20(3):358-363.